Halozyme (HALO)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$122.96-5.66%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · HALO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -4.2% |
| Our one-year growth estimate | diamond | 22.4% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 26.7 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name has been missing across recent quarters and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers · Company calendar date is not available
HALO — capital allocation — Creation of a Direct Financial Obligation or an Obligation under an Off-Balan…
Dated 2026-09-22
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in
Why it matters: Halozyme bought back $333 million of shares in Q2 and set a $400 million minimum for 2026. The next report can show if it stays on pace.
Supportive ifThe next company update shows total 2026 share repurchases of at least $400 million by year-end.
Worry ifThe company reports less than $400 million in total 2026 share repurchases by year-end.
Why it matters: Operating income rose to $287.7 million in Q2. A lower Q3 result could show that higher costs are weighing on earnings.
Worry ifQ3 operating income is below $287.7 million, the Q2 2026 level.
Less concerning ifQ3 operating income is at least $287.7 million.
Why it matters: Halozyme plans about $60 million in 2026 investments in these technologies. A study step would show the spending is moving programs forward.
Watch forHalozyme names a new Hypercon or Surf Bio partner program that enters a clinical study. Or it reports a clear study milestone.
Also watch forHalozyme reports a delay, stop, or cut to a named Hypercon or Surf Bio program. Or it raises its planned 2026 investment above about $60 million without a program step.
Why it matters: Royalties drove most of Q2 growth. Q3 results will test whether that growth stays on track for the full-year goal.
Worry ifQ3 year-to-date royalty revenue falls below the pace needed to reach $1.220 billion for 2026.
Less concerning ifQ3 year-to-date royalty revenue meets or exceeds the pace needed to reach $1.220 billion for 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$115 on $10,000 · ±1.2% | How much price usually moves either way. |
| Bad day | $268 loss on $10,000 · 2.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,413 loss on $10,000 · 24.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.